Soft biological tissues are important constituents that influence human physiology and disease since they impact cell behavior during tissue development, maintenance and repair. Most existing methods ...

Labcorp Oncology, Director, Medical Affairs and Adjunct Assistant Professor, Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic ...

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients. Carrying out plasma next-generation sequencing ...

Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...

Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone. There are two popular testing strategies ...

An ultrasound is one of several tests that can help confirm a soft tissue sarcoma diagnosis. Ultrasounds create detailed images showing the size and location of tumors. These images can also be used ...

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...

A new study highlights the potential of whole genome and transcriptome sequencing (WGTS) to improve precision treatment and identify the tissue of origin for cancers whose primary site is unknown, ...

Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Animal testing could slowly be replaced with experiments using ...